Document is current
Any future updates will be listed below
-
Authors
Turunen, Jillyn R.
Kumthekar, Priya
Ahmed, Atique U.
-
Funding
Funding for this research was provided by:
National Institutes of Health (1R01NS096376, 1R01NS096376, 1R01NS096376)
- License Information
-
More Information
Article History
Received: 7 August 2024
Accepted: 15 February 2025
First Online: 19 May 2025
Declarations
:
: Not applicable.
: Not applicable.
: JRT and AUA declare no competing interests. PK declares: Consulting Fee (e.g., Advisory Board): Enclear Therapies, Affinia Therapeutics, Biocept, Janssen, Bioclinica, Novocure, Mirati, Servier, Roche, Telix Pharmaceuticals, PlusTherapeutics, Belay Diagnostics, Biodexa Data Safety Monitoring Community: BPGBio, In8bio Speaker's Bureau: Seagen Contracted Research: Genentech, Novocure, DNAtrix, Orbus Therapeutics, Servier, Plus Therapeutics Provisional Patent issued for the treatment of Leptomeningeal Carcinomatosis with ANG1005 Patent Number: WO2016/205367.
